Virbac has launched Pronefra, a palatable phosphate-binder to aid with the management of chronic kidney disease (CKD) in cats and dogs.
The company says that managing blood phosphate levels is regarded as one of the most important aspects of managing CKD, with various studies showing the benefits of restricting phosphate in the diet1,2. The company also points to a study which shows that Pronefra, which contains two intestinal phosphate binders: calcium carbonate and magnesium carbonate, can significantly decrease serum phosphate levels3.
In addition, Pronefra also contains:
Virbac is at pains to stress that palatability has been a focus of Pronefra's development as it is an essential attribute for a product aimed at often inappetant animals.
Pronefra is presented in a liquid formulation for ease of use and should be mixed with food or given orally (it can be syringed) at meal times.
Virbac is providing a practice pack of support materials to practices, including a pet health recording book for clients to aid in compliance and other educational tools for vets, nurses and clients.
Simon Boulton MRCVS, Marketing Manager for Companion Animals, said: "CKD causes a vicious circle of deterioration but good management can increase both the quality of life and life expectancy of affected animals.
"We are delighted to launch Pronefra in the UK, following a 'sell-out' launch in mainland Europe, as a new option to aid in the management of CKD."
References
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.
"various studies showing the benefits of restricting phosphate in the diet"
The studies in the detailer I was shown were comparing survival of cats on normal or renal diets, which are more than just reduced phosphate - eg. reduced protein also. To suggest that the effect of just a phosphate binder is expected to be the same is stretching the data?
Also, study 3. is of cats, none of which had renal failure at the start of the study, for a product for use in renal failure cats???